In vivo generation of dendritic cells by intramuscular codelivery of FLT3 ligand and GM-CSF plasmids

Molecular Therapy

Volumn 6, Issue 3, 2002, Pages 407-414

  Peretz, Yoav ^a   Zhou, Zheng Frank ^a   Halwani, Fawaz ^a   Prud'homme, Gérald J ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Antigen presenting cell; Dendritic cells; Electroporation; FLT3 L; Gene therapy; GM CSF; Muscle; Plasmid

Indexed keywords

B7 ANTIGEN; BIOLOGICAL MARKER; CD11B ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; COMPLEMENTARY DNA; CYTOKINE; FLT3 LIGAND; GLYCOPROTEIN P 15095; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PLASMID DNA; PLASMID VECTOR;

ANIMAL CELL; ANTIGEN PRESENTATION; ARTICLE; BONE MARROW CELL; CELL COUNT; CELL SUSPENSION; CELL TYPE; CONTROLLED STUDY; CYTOCHEMISTRY; DENDRITIC CELL; DRUG EFFICACY; ELECTROPORATION; FEMALE; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GENETIC CODE; IN VIVO STUDY; LYMPHOCYTE ACTIVATION; LYMPHOID CELL; METHODOLOGY; MIXED LYMPHOCYTE CULTURE; MOUSE; NONHUMAN; PLASMID; SPLEEN CELL; T LYMPHOCYTE;

ANIMALIA;

EID: 0036764791     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2002.0677     Document Type: Article

References (31)

1. Bell, D., Young, J. W., and Banchereau, J. (1999). Dendritic cells. Adv. Immunol. 72: 255-324.
2. Antonysamy, M. A., et al. (1998). FLT-3 ligand increases microchimerism but can prevent the therapeutic effect of donor bone marrow in transiently immunosuppressed cardiac allograft recipients. J. Immunol. 160: 4106-4113.
3. Banchereau, J., et al. (2000). Immunobiology of dendritic cells. Annu. Rev. Immunol. 18: 767-811.
4. Heath, W. R., and Carbone, F. R. (2001). Cross-presentation, dendritic cells, tolerance and immunity. Annu. Rev. Immunol. 19: 47-64.
5. Lynch, D. H., et al. (1997). FLT3-L ligand induces tumor regression and antitumor immune responses in vivo. Nat. Med. 3: 625-631.
6. Fong, L., et al. (2001). Altered peptide ligand vaccination with FLT3 ligand expanded dendritic cells for tumor immunotherapy. Proc. Natl. Acad. Sci. USA 98: 8809-8814, doi:10.1073/pnas.141226398.
7. Williamson, E., Westrich, G. M., and Viney, J. L. (1999). Modulating dendritic cells to optimize mucosal immunization protocols. J. Immunol. 163: 3668-3675.
8. Lutz, M. B., et al. (1999). An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J. Immunol. Methods 223: 77-92.
9. Winzler, C., et al. (1997). Maturation stages of mouse dendritic cells in growth factor-dependent long-term cultures. J. Exp. Med. 185: 317-328.
10. Berthier, R., Martinon-Ego, C., Laharie, A. M., and Marche, P. N. (2000). A two-step culture method starting with early growth factors permits enhanced production of functional DCs from murine splenocytes. J. Immunol. Methods 239: 95-107.
11. Saunders, D., et al. (1996). Dendritic cell development in culture from thymic precursor cells in the absence of granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 184: 2185-2196.
12. He, Y., et al. (2000). Intravenous injection of naked DNA encoding secreted FLT3-ligand dramatically increases the number of dendritic cells and natural killer cells in vivo. Hum. Gene. Ther. 11: 547-554.
13. Lotze, M. T., et al. (1999). Dendritic cell therapy of cancer and HIV infection. In Dendritic Cells: Biology and Clinical Applications (M. T. Lotze and A. W. Thomson, Eds.), pp 459-485. Academic Press, San Diego.
14. Brasel, K., et al. (1996). Hematologic effects of FLT3-ligand in vivo in mice. Blood 88: 2004-2012.
15. Gabbianelli, M., et al. (1995). Multi-level effects of Flt3 ligand on human hematopoiesis: expansion of putative stem cells and proliferation of granulomonocytic progenitors/monocytic precursors. Blood 86: 1661-1670.
16. Maraskovsky, E., et al. (1996). Dramatic increase in the numbers of functionally mature dendritic cells in FLT3-ligand-treated mice: multiple dendritic cell subpopulations identified. J. Exp. Med. 184: 1953-1962.
17. Maraskovsky, E., Pulendran, B., and Shortman, K. (1999). Lymphoid related dendritic cells. In Dendritic cells: Biology and Clinical Applications (M. T. Lotze and A. W. Thomson, Eds.), pp 93-107. Academic Press, San Diego.
18. Lyman, S. D., and Jacobsen, S. E. W. (1998). C-kit ligand and FLT3-ligand: stem/progenitor cell factors with overlapping yet distinctive activities. Blood 91: 1101-1134.
19. Armitage, J. O. (1998). Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor. Blood 92: 4491-4508.
20. Pulendran, B., et al. (1997). Developmental pathways of dendritic cells in vivo. J. Immunol. 159: 2222-2231.
21. Wu, L., et al. (2001). Development of thymic and splenic dendritic cell populations from different hemopoietic precursors. Blood 98: 3376-3382.
22. Shortman, K., and Liu, Y.-J. (2002). Mouse and human dendritic cell subtypes. Nat. Rev. Immunol. 2: 151-161, doi:10.1038/nri746.
23. Parajuli, P., et al. (2001). FLT3 ligand and granulocyte-macrophage colony-stimulating factor preferentially expand and stimulate different dendritic and T-cell subsets. Exp. Hematol. 29: 1185-1193.
24. Brasel, K., et al. (1997). FLT3-ligand synergizes with granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor to mobilize hematopoietic progenitor cells into the peripheral blood of mice. Blood 90: 3781-3788.
25. Reis e Sousa, C., et al. (1997). In vivo microbial stimulation induces rapid CD40 ligand-independent production of interleukin 12 by dendritic cells and their redistribution to T cell areas. J. Exp. Med. 186: 1819-1829.
26. Kelleher, P., and Knight, S. C. (1998). IL-12 increases CD80 expression and the stimulatory capacity of bone marrow-derived dendritic cells. Int. Immunol. 10: 749-755.
27. Hartikka, J., et al. (1996). An improved plasmid DNA expression vector for direct injection into skeletal muscle. Hum. Gene. Ther. 7: 1205-1217.
28. Prud'homme, G. J., and Chang, Y. (1999). Prevention of autoimmune diabetes by intramuscular gene therapy with a nonviral vector encoding an interferon-γ receptor/IgG1 fusion protein. Gene Ther. 6: 771-777.
29. Song, K., Chang, Y., and Prud'homme, G. J. (2000). IL-12 plasmid-enhanced DNA vaccination against carcinoembryonic antigen (CEA) studied in immune-gene knockout mice. Gene Ther. 7: 1527-1535.
30. Leenen, P. J. M., et al. (1998). Heterogeneity of mouse spleen dendritic cells: In vivo phagocytic activity, expression of macrophages markers, and subpopulation turnover. J. Immunol. 160: 2166-2173.
31. Prud'homme, G. J., Chang, Y., and Li, X. (2002). Immunoinhibitory DNA vaccine protects against autoimmune diabetes through cDNA encoding a selective CTLA-4 (CD152) ligand. Hum. Gene. Ther. 13: 395-406.